Safety of Intraparenchymal Injection of Allogenic Placenta Mesenchymal Stem Cells Derived Exosome in Patients Undergoing Decompressive Craniectomy Following Malignant Middle Cerebral Artery Infarct, A Pilot Randomized Clinical Trial.
Allogenic mesenchymal stem cell
decompressive craniectomy
exosome
mMCAI
Journal
International journal of preventive medicine
ISSN: 2008-7802
Titre abrégé: Int J Prev Med
Pays: Iran
ID NLM: 101535380
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
10
2021
accepted:
12
10
2021
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
15
3
2022
Statut:
epublish
Résumé
Malignant middle cerebral artery infarct (mMCAI) largely contributes to high mortality and physical disability among adults. Surviving individuals may not have proper outcomes and suffer from severe lasting disabilities. Utilization of stem cells and paracrine factor for regenerative purposes is considered as a potential strategy for patients with neurological deficits. While preclinical stroke studies have shown that mesenchymal stem cells (MSCs) reduce post-treatment neurological deficits and prevent disability and also promote recovery, few randomized clinical trials (RCT) have assessed exosome therapy in humans. In this RCT, we assessed the safety of intraparenchymal injection placenta MSC-derived Exosome in mMCAI patients with average age of 62 years between January, 2019, till September, 2020. The study was done in a single-center as an open-label RCT, with a 3-months follow-up. Primary outcomes assessed the safety and also disability indexes were followed. Five mMCAI patients were included with mean NIHSS: 17.6 ± 5.02. The mean MRS was 3.25 ± 0.95 in three patients. No serious adverse events were observed. Hematoma or local reaction as excessive edema were not seen at the site of injection. Intraparenchymal implantation of MSC-EXO showed no post-interventional adverse effects in five ischemic stroke patients. It is proposed Local injection Exosome treatment following mMCAI can be safe and in future, it would be applied as a supportive, restorative and preventive treatment in patients who suffer from acute ischemic stroke and post ischemic disability.
Sections du résumé
Background
UNASSIGNED
Malignant middle cerebral artery infarct (mMCAI) largely contributes to high mortality and physical disability among adults. Surviving individuals may not have proper outcomes and suffer from severe lasting disabilities. Utilization of stem cells and paracrine factor for regenerative purposes is considered as a potential strategy for patients with neurological deficits. While preclinical stroke studies have shown that mesenchymal stem cells (MSCs) reduce post-treatment neurological deficits and prevent disability and also promote recovery, few randomized clinical trials (RCT) have assessed exosome therapy in humans.
Methods
UNASSIGNED
In this RCT, we assessed the safety of intraparenchymal injection placenta MSC-derived Exosome in mMCAI patients with average age of 62 years between January, 2019, till September, 2020. The study was done in a single-center as an open-label RCT, with a 3-months follow-up. Primary outcomes assessed the safety and also disability indexes were followed.
Results
UNASSIGNED
Five mMCAI patients were included with mean NIHSS: 17.6 ± 5.02. The mean MRS was 3.25 ± 0.95 in three patients. No serious adverse events were observed. Hematoma or local reaction as excessive edema were not seen at the site of injection.
Conclusions
UNASSIGNED
Intraparenchymal implantation of MSC-EXO showed no post-interventional adverse effects in five ischemic stroke patients. It is proposed Local injection Exosome treatment following mMCAI can be safe and in future, it would be applied as a supportive, restorative and preventive treatment in patients who suffer from acute ischemic stroke and post ischemic disability.
Identifiants
pubmed: 35281985
doi: 10.4103/ijpvm.ijpvm_441_21
pii: IJPVM-13-7
pmc: PMC8883670
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7Informations de copyright
Copyright: © 2022 International Journal of Preventive Medicine.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Stem Cell Rev Rep. 2021 Apr;17(2):428-438
pubmed: 32935221
Cytotherapy. 2011 Jul;13(6):675-85
pubmed: 21231804
Stroke. 2011 Jul;42(7):1952-5
pubmed: 21636813
N Engl J Med. 2015 Mar 12;372(11):1009-18
pubmed: 25671797
Int J Mol Sci. 2020 Sep 20;21(18):
pubmed: 32962207
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Stem Cells Int. 2013;2013:732742
pubmed: 24000286
Stem Cells Transl Med. 2020 Apr;9(4):499-517
pubmed: 31943851
Nat Rev Neurosci. 2003 May;4(5):399-415
pubmed: 12728267
World Neurosurg. 2019 Mar;123:8-16
pubmed: 30500591
Postgrad Med J. 2010 Apr;86(1014):235-42
pubmed: 20354047
J Cereb Blood Flow Metab. 2013 Nov;33(11):1711-5
pubmed: 23963371
Sci Rep. 2017 Mar 16;7:44433
pubmed: 28300134
Stem Cell Res Ther. 2015 Jun 19;6:121
pubmed: 26088123
Stem Cells Transl Med. 2015 Oct;4(10):1131-43
pubmed: 26339036
Oncotarget. 2016 Nov 15;7(46):74537-74556
pubmed: 27793019
Lancet Neurol. 2007 Mar;6(3):215-22
pubmed: 17303527
Surg Neurol Int. 2014 May 15;5:72
pubmed: 24991475
Stroke. 2004 Feb;35(2):539-43
pubmed: 14707232
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
World Neurosurg. 2016 Dec;96:383-389
pubmed: 27639522
Ann Neurol. 2009 Jul;66(1):6-10
pubmed: 19681102
Minerva Med. 2019 Oct 14;:
pubmed: 31638364
Nat Rev Neurol. 2019 Apr;15(4):193-203
pubmed: 30700824